HRP20200478T1 - Farmakofor za indukciju faktora nekroze tumora (tnf) srodnog apoptoza-inducirajućeg liganda - Google Patents

Farmakofor za indukciju faktora nekroze tumora (tnf) srodnog apoptoza-inducirajućeg liganda Download PDF

Info

Publication number
HRP20200478T1
HRP20200478T1 HRP20200478TT HRP20200478T HRP20200478T1 HR P20200478 T1 HRP20200478 T1 HR P20200478T1 HR P20200478T T HRP20200478T T HR P20200478TT HR P20200478 T HRP20200478 T HR P20200478T HR P20200478 T1 HRP20200478 T1 HR P20200478T1
Authority
HR
Croatia
Prior art keywords
compound
formula
alkyl
compound according
pharmaceutically acceptable
Prior art date
Application number
HRP20200478TT
Other languages
English (en)
Croatian (hr)
Inventor
Kim D. Janda
Nicholas T. JACOB
Jonathan W. LOCKNER
Original Assignee
The Scripps Research Institute La Jolla
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Scripps Research Institute La Jolla filed Critical The Scripps Research Institute La Jolla
Publication of HRP20200478T1 publication Critical patent/HRP20200478T1/hr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HRP20200478TT 2014-03-31 2015-03-30 Farmakofor za indukciju faktora nekroze tumora (tnf) srodnog apoptoza-inducirajućeg liganda HRP20200478T1 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461972689P 2014-03-31 2014-03-31
PCT/US2015/023362 WO2015153468A1 (en) 2014-03-31 2015-03-30 Pharmacophore for trail induction
EP15772254.7A EP3125898B1 (en) 2014-03-31 2015-03-30 Pharmacophore for trail induction

Publications (1)

Publication Number Publication Date
HRP20200478T1 true HRP20200478T1 (hr) 2020-07-24

Family

ID=54241169

Family Applications (2)

Application Number Title Priority Date Filing Date
HRP20200478TT HRP20200478T1 (hr) 2014-03-31 2015-03-30 Farmakofor za indukciju faktora nekroze tumora (tnf) srodnog apoptoza-inducirajućeg liganda
HRP20241680TT HRP20241680T1 (hr) 2014-03-31 2015-03-30 Farmakofor za trail indukciju

Family Applications After (1)

Application Number Title Priority Date Filing Date
HRP20241680TT HRP20241680T1 (hr) 2014-03-31 2015-03-30 Farmakofor za trail indukciju

Country Status (20)

Country Link
US (5) US10239877B2 (enExample)
EP (3) EP3125898B1 (enExample)
JP (4) JP6756435B2 (enExample)
KR (2) KR102611067B1 (enExample)
CN (2) CN111499636B (enExample)
AU (5) AU2015241069B2 (enExample)
CA (2) CA3158795A1 (enExample)
CY (1) CY1123093T1 (enExample)
DK (2) DK3125898T3 (enExample)
ES (2) ES2779979T3 (enExample)
FI (1) FI3662910T3 (enExample)
HR (2) HRP20200478T1 (enExample)
HU (2) HUE069651T2 (enExample)
LT (2) LT3125898T (enExample)
PL (2) PL3125898T3 (enExample)
PT (2) PT3125898T (enExample)
RS (2) RS60163B1 (enExample)
SI (2) SI3662910T1 (enExample)
SM (2) SMT202000219T1 (enExample)
WO (1) WO2015153468A1 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9376437B2 (en) 2013-03-13 2016-06-28 Oncoceutics, Inc 7-benzyl-4-(2-methylbenzyl)-2,4,6,7,8,9-hexahydroimidazo[1,2-a]pyrido[3,4-e]pyrimidin-5(1H)-one, salts thereof and methods of using the same in combination therapy
PL2968294T3 (pl) 2013-03-13 2019-10-31 Oncoceutics Inc 7-Benzylo-10-(2-metylobenzylo)-2,6,7,8,9,10-heksahydroimidazo[1,2-a]pirydo[4,3-d]pirymidyn-5(3H)-on do zastosowania w leczeniu nowotworu
US9688679B2 (en) 2013-03-13 2017-06-27 Oncoceutics, Inc. 7-benzyl-4-(methylbenzyl)-2,4,6,7,8,9-hexahydroimidazo[1,2-A]pyrido[3,4-E]pyrimidin-5 (1H)-one, salts thereof and methods of using the same in combination therapy
SMT201900291T1 (it) * 2013-11-15 2019-07-11 Oncoceutics Inc 7-benzil-4-(2-metilbenzil)-2,4,6,7,8,9-esaidriomidazo[1,2-a]pirido[3,4-e]pirimidin-5(1h)-one, suoi sali e metodi d'uso
HUE069651T2 (hu) 2014-03-31 2025-03-28 Scripps Research Inst Farmakofór TRAIL indukcióra
SMT202500087T1 (it) * 2015-01-30 2025-03-12 Oncoceutics Inc Derivati di 7-benzil-4-(2-metilbenzil)-2,4,6,7,8,9-esaidroimidazo[1,2-a]pirido[3,4-e]pirimidin-5(1h)-one, loro sali e loro uso in terapia
CN104860948B (zh) 2015-05-15 2017-09-26 南京盖特医药技术有限公司 咪唑并嘧啶酮类化合物及其制备方法和应用
WO2017132661A2 (en) * 2016-01-29 2017-08-03 Oncoceutics, Inc. G protein-coupled receptor (gpcr) modulation by imipridones
US11091483B2 (en) 2016-08-12 2021-08-17 Madera Therapeutics, LLC Protein kinase regulators
US10172862B2 (en) 2017-01-30 2019-01-08 Oncoceutics, Inc. Imipridones for gliomas
GB2596010B (en) * 2019-02-11 2023-03-01 Madera Therapeutics Llc Use of caseinolytic protease P function as a biomarker of drug response to imipridone-like agents
AU2020228047B2 (en) 2019-02-27 2025-11-20 Madera Therapeutics, LLC Use of caseinolytic protease P function as a biomarker of drug response to imipridone-like agents
BR112023002082A2 (pt) 2020-08-06 2023-05-09 Eoetvoes Lorand Tudomanyegyetem Síntese de derivados de imipridona e sua avaliação para sua atividade anticancerígena
CN115448921B (zh) * 2021-06-08 2023-08-01 四川大学 一类咪唑烷并嘧啶酮化合物及在治疗HsClpP介导的疾病中的用途
CN116751199B (zh) * 2023-06-02 2025-03-18 中国科学院基础医学与肿瘤研究所(筹) 一种线粒体蛋白酶靶向嵌合体、制备方法及用途
EP4684834A1 (de) * 2024-07-26 2026-01-28 BRIU GmbH Kristallformen onkologisch wirksamer imipridone und verfahren zu deren herstellung

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE786028A (fr) * 1971-07-08 1973-01-08 Boehringer Sohn Ingelheim 2,3-dihydro-oxo-imidazo(1,2-a)-pyrimidines, leurs sels d'addition avec des acides et procedes pour les fabriquer
DE2150062A1 (de) 1971-10-07 1973-04-12 Boehringer Sohn Ingelheim Imidazo- eckige klammer auf 1,2-a eckige klammer zu -pyrido- eckige klammer auf 4,3-d eckige klammer zu -pyrimidine, deren saeureadditionssalze und verfahren zu deren herstellung
JPS5374893A (en) 1976-12-15 1978-07-03 Fujitsu Ltd Driving method for semiconductor photosensitive device
JPS6132833U (ja) 1984-07-31 1986-02-27 日信工業株式会社 デイスクブレ−キ装置
EP1517904A4 (en) * 2002-05-23 2007-02-21 Merck & Co Inc INHIBITORS OF MITOTIC KINESINE
PT2303264T (pt) * 2008-06-09 2018-05-14 Allergan Inc Métodos de tratamento de condições mediadas adrenérgicas alfa utilizando derivados de imidazolina
CA2795952A1 (en) * 2010-04-16 2011-10-20 Curis, Inc. Treatment of cancers having k-ras mutations
WO2012078448A1 (en) * 2010-12-06 2012-06-14 Schering Corporation Tricyclic heterocycles useful as dipeptidyl peptidase-iv inhibitors
TWI658047B (zh) * 2011-03-15 2019-05-01 吉斯藥品公司 異唑啶衍生物
WO2012138789A2 (en) * 2011-04-04 2012-10-11 Netherlands Cancer Institute Methods and compositions for predicting resistance to anticancer treatment
RS67757B1 (sr) 2011-04-29 2026-03-31 Penn State Res Found Indukcija malim molekulom trail gena u normalnim i tumorskim ćelijama kao antikancerska terapija
WO2015073072A1 (en) * 2013-11-15 2015-05-21 Oncoceutics, Inc. 7-benzyl-4-(2-methylbenzyl)-2,4,6,7,8,9-hexahydroimidazo[1,2-a]pyrido[3,4-e]pyrimidin-5(1h)-one
US9376437B2 (en) * 2013-03-13 2016-06-28 Oncoceutics, Inc 7-benzyl-4-(2-methylbenzyl)-2,4,6,7,8,9-hexahydroimidazo[1,2-a]pyrido[3,4-e]pyrimidin-5(1H)-one, salts thereof and methods of using the same in combination therapy
US9688679B2 (en) 2013-03-13 2017-06-27 Oncoceutics, Inc. 7-benzyl-4-(methylbenzyl)-2,4,6,7,8,9-hexahydroimidazo[1,2-A]pyrido[3,4-E]pyrimidin-5 (1H)-one, salts thereof and methods of using the same in combination therapy
PL2968294T3 (pl) * 2013-03-13 2019-10-31 Oncoceutics Inc 7-Benzylo-10-(2-metylobenzylo)-2,6,7,8,9,10-heksahydroimidazo[1,2-a]pirydo[4,3-d]pirymidyn-5(3H)-on do zastosowania w leczeniu nowotworu
US9181237B2 (en) * 2013-10-04 2015-11-10 Mallinckrodt Llc Substituted berbines and their synthesis
HUE069651T2 (hu) 2014-03-31 2025-03-28 Scripps Research Inst Farmakofór TRAIL indukcióra

Also Published As

Publication number Publication date
EP4470617A2 (en) 2024-12-04
PL3125898T3 (pl) 2020-11-16
ES2779979T3 (es) 2020-08-21
EP4470617A3 (en) 2025-02-26
KR102611067B1 (ko) 2023-12-06
RS60163B1 (sr) 2020-05-29
US10239877B2 (en) 2019-03-26
EP3125898A4 (en) 2017-08-16
PT3125898T (pt) 2020-04-01
PT3662910T (pt) 2024-11-27
KR20220163533A (ko) 2022-12-09
LT3125898T (lt) 2020-04-10
HUE049013T2 (hu) 2020-08-28
AU2015241069B2 (en) 2020-10-15
US10633385B2 (en) 2020-04-28
AU2015241069A1 (en) 2016-10-20
CA2944452C (en) 2022-07-19
JP6756435B2 (ja) 2020-09-16
CN106456643B (zh) 2020-04-17
PL3662910T3 (pl) 2025-08-11
CA3158795A1 (en) 2015-10-08
DK3662910T3 (en) 2024-11-04
US12630550B2 (en) 2026-05-19
AU2024204977B2 (en) 2026-04-16
CN106456643A (zh) 2017-02-22
JP6873201B2 (ja) 2021-05-19
ES2999685T3 (en) 2025-02-26
CN111499636A (zh) 2020-08-07
SMT202400497T1 (it) 2025-01-14
RS66254B1 (sr) 2024-12-31
CY1123093T1 (el) 2021-10-29
US20220002300A1 (en) 2022-01-06
KR20160138513A (ko) 2016-12-05
US20200283440A1 (en) 2020-09-10
US20170107221A1 (en) 2017-04-20
HUE069651T2 (hu) 2025-03-28
SI3125898T1 (sl) 2020-07-31
JP2020002170A (ja) 2020-01-09
JP2017511321A (ja) 2017-04-20
US20190284188A1 (en) 2019-09-19
EP3662910A1 (en) 2020-06-10
JP2021119157A (ja) 2021-08-12
JP2023022184A (ja) 2023-02-14
AU2026206080A1 (en) 2026-07-30
AU2024204977A1 (en) 2024-08-08
US11891392B2 (en) 2024-02-06
DK3125898T3 (da) 2020-03-30
CN111499636B (zh) 2023-01-13
EP3662910B1 (en) 2024-09-18
CA2944452A1 (en) 2015-10-08
EP3125898A1 (en) 2017-02-08
US20240190877A1 (en) 2024-06-13
JP7688245B2 (ja) 2025-06-04
LT3662910T (lt) 2024-12-27
JP7186256B2 (ja) 2022-12-08
WO2015153468A1 (en) 2015-10-08
KR102473930B1 (ko) 2022-12-05
EP3125898B1 (en) 2019-12-25
SI3662910T1 (sl) 2025-05-30
AU2022283729A1 (en) 2023-02-02
HRP20241680T1 (hr) 2025-02-28
SMT202000219T1 (it) 2020-05-08
AU2020286314A1 (en) 2021-01-21
FI3662910T3 (fi) 2024-10-31

Similar Documents

Publication Publication Date Title
MD3313851T2 (ro) Noi derivați hidroxiester, procedeu pentru prepararea lor și compoziții farmaceutice care îi conțin
CO2019003349A2 (es) Compuestos de benzo[b]tiofeno como agonistas de sting
EA201790407A1 (ru) Зонды для визуализации белка хантингтина
EP3431075C0 (en) EDARAVONDAR FORM
BR112017024917A2 (pt) síntese de compostos heterocíclicos
MA43242A (fr) Mélange pour traiter des engrais à base d'urée
AR097082A1 (es) Compuestos terapéuticamente activos y sus métodos de uso
EP2720743A4 (en) MASK FOR THE ADMINISTRATION OF A MEDICAMENT TO BE TAKEN
EP3347707A4 (en) REFLECTION IMAGING FOR THE PRECISION AGRICULTURE
PH12016500885A1 (en) Novel heterocyclic compounds
IN2014MN02106A (enExample)
MA39866A (fr) Amides 2-amino-6-méthyl-4,4a,5,6-tétrahydropyrano[3,4-d][1,3]thiazin-8a(8h)-yl-1,3-thiazol-4-yle
EP3049486A4 (en) INKJET INK SET
MX373716B (es) Compuesto de pirazol-amida y sus usos farmaceuticos.
NZ732213A (en) Lanthionine synthetase c-like 2-based therapeutics
EP3409108A4 (en) BED LINEN FOR PET BED
EA201790400A1 (ru) Зонды для визуализации белка хантингтина
EA201790432A1 (ru) Зонды для визуализации белка хантингтина
EP3283128A4 (en) TRANSMETALIZATION PROCEDURE FOR SYNTHESIS OF PET AND SPECT CONTRASTANTS
EP3433325A4 (en) INKJET INK SET
EP3445428A4 (en) SPACER DEVICE FOR AN INHALATOR
AR095097A1 (es) Compuestos de fenoxietoxi
MX2016002718A (es) Derivados de ceto-imidazopiridina como moduladores del receptor huerfano relacionado con receptor retinoide (porc).
EP3313380A4 (en) COMPOSITION FOR THE ADMINISTRATION OF ACTIVE SUBSTANCES TO AN ANIMAL
BR112019001447A2 (pt) método de produção para composto pirazol-amida